# Xenon Pharmaceuticals Inc.: overview

XENE · Nasdaq · CIK 1582313 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xene.md) · [Financials](/companies/xene/financials.md) · [Filings](/companies/xene/filings.md) · [Insiders](/companies/xene/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-338244.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-338244).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001193125-25-262646.md) | [0.0 d](/filings/0001193125-26-076650.md) | [7.5](/filings/0001193125-26-212153.md) | [0.0](/filings/0001193125-26-338244.md) | [0.0](/filings/0001193125-25-262646.md) | [0.0 d](/filings/0001193125-26-076650.md) | [0.0](/filings/0001193125-26-212153.md) | [0.0](/filings/0001193125-26-338244.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(969.8%)](/filings/0001193125-26-212153.md) | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | [(867.3%)](/filings/0001193125-26-338244.md) | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.81)](/filings/0001193125-25-262646.md) | not reported | [(0.83)](/filings/0001193125-26-212153.md) | [(1.07)](/filings/0001193125-26-338244.md) | [(1.15)](/filings/0001193125-25-262646.md) | not reported | [(1.17)](/filings/0001193125-26-212153.md) | [(1.11)](/filings/0001193125-26-338244.md) |
| Free cash flow | $m | [(50.3) d](/filings/0001193125-25-262646.md) | [(55.2) d](/filings/0001193125-26-076650.md) | [(61.7)](/filings/0001193125-26-212153.md) | [(64.4) d](/filings/0001193125-26-338244.md) | [(72.0) d](/filings/0001193125-25-262646.md) | [(81.8) d](/filings/0001193125-26-076650.md) | [(89.0)](/filings/0001193125-26-212153.md) | [(95.7) d](/filings/0001193125-26-338244.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [18.4](/filings/0000950170-24-023177.md) | [9.4](/filings/0000950170-25-029149.md) | [0.0](/filings/0001193125-26-076650.md) | [0.0](/filings/0001193125-26-076650.md) | [7.5](/filings/0001193125-26-076650.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(428.4%)](/filings/0000950170-24-023177.md) | [(1368.9%)](/filings/0000950170-25-029149.md) | not reported | not reported | [(4974.3%)](/filings/0001193125-26-076650.md) |
| Net margin | % | [(427.8%)](/filings/0000950170-24-023177.md) | [(1328.9%)](/filings/0000950170-25-029149.md) | not reported | not reported | [(4612.1%)](/filings/0001193125-26-076650.md) |
| Diluted EPS | $ per share | [(1.77)](/filings/0000950170-24-023177.md) | [(2.06)](/filings/0000950170-25-029149.md) | [(2.73)](/filings/0001193125-26-076650.md) | [(3.01)](/filings/0001193125-26-076650.md) | [(4.36)](/filings/0001193125-26-076650.md) |
| Free cash flow | $m | [(71.6)](/filings/0000950170-24-023177.md) | [(104)](/filings/0000950170-25-029149.md) | [(157)](/filings/0001193125-26-076650.md) | [(184)](/filings/0001193125-26-076650.md) | [(280)](/filings/0001193125-26-076650.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xene/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $582.4m | 9,647,998 |  | Reduced −1,170,493 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $454.1m | 7,522,482 |  | Added +1,882,364 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $348.7m | 5,777,777 |  | Unchanged |
| [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $275.9m | 4,570,556 |  | Added +165,244 |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $266.7m | 4,418,557 |  | Reduced −73,096 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $252.7m | 4,186,519 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $242.9m | 4,175,982 |  | Not compared |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $157.4m | 2,617,360 |  | Added +693,750 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $142.5m | 2,361,639 |  | Reduced −313,088 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $118.9m | 1,969,629 |  | Added +249,096 |

## Recent filings

[All 796 filings](/companies/xene/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 20:31 ET | [10-Q](/filings/0001193125-26-338244.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338244 |
| 2026-08-06 | 20:11 ET | [8-K](/filings/0001193125-26-338019.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-338019 |
| 2026-06-03 | 20:02 ET | [8-K](/filings/0001193125-26-255396.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-255396 |
| 2026-05-07 | 20:35 ET | [10-Q](/filings/0001193125-26-212153.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212153 |
| 2026-05-07 | 20:02 ET | [8-K](/filings/0001193125-26-211843.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-211843 |
| 2026-04-22 | 20:02 ET | [DEF 14A](/filings/0001193125-26-170320.md) | Proxy statement, period 2026-04-22 | 0001193125-26-170320 |
| 2026-04-13 | 20:01 ET | [8-K](/filings/0001193125-26-152834.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-152834 |
| 2026-03-13 | 20:10 ET | [8-K](/filings/0001193125-26-106144.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-106144 |
| 2026-03-12 | 20:17 ET | [8-K](/filings/0001193125-26-104199.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-104199 |
| 2026-03-09 | 11:36 ET | [8-K](/filings/0001193125-26-097577.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-097577 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076650.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2d040414-2821-4f53-b305-5bbd74c22b23)

## About the filer

- CIK: 1582313
- Tickers: XENE
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: A1
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.